Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the ...
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...
Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.
Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...
Hosted on MSN2d
Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 ProjectionsShares of Eli Lilly & Co. dropped over 7% on Tuesday morning, reaching levels last seen in late November and marking the ...
Peer Conversations explores successful leadership through the personal and professional choices of the most influential ...
INDIANAPOLIS, Jan. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO ...
Key Takeaways Eli Lilly shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year.The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback